The company reported a net loss of $148 million for FY26, driven by increased R&D and administrative expenses as it advanced its lead programs HLP003 and HLP004 through late-stage clinical trials. Cash reserves rose to $157 million following major equity financings, with topline Phase 3 data for HLP003 in MDD expected in Q4 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.